StimLabs launches DermaForm from Geistlich on the US market
Wolhusen/Schlieren/Roswell - StimLabs from Roswell has launched DermaForm, a collagen product for wound treatment approved in February 2026, on the North American market. It was developed by Geistlich Pharma AG, which is located in Wolhusen and is a subsidiary of the Schlieren-based Geistlich Group.
StimLabs has launched DermaForm on the US market. Developed by Geistlich Pharma AG (Geistlich) as a wound care solution, DermaForm was approved in February 2026 by the United States Food and Drug Administration (FDA). Geistlich is based in Wolhusen in the Swiss canton of Lucerne and forms part of the Geistlich Group, headquartered in Schlieren in the canton of Zurich.
According to a statement issued by Geistlich, DermaForm will be exclusively distributed in the USA by its wound care partner StimLabs. The regenerative medicine company is headquartered in Roswell in the US State of Georgia.
DermaForm is based on a specially developed, porous, collagen-based scaffold that supports wound care, tissue protection and wound healing. It is biocompatible and can be applied directly from the vial. Over time it naturally blends into the wound bed.
“DermaForm is the result of Geistlich’s pioneering spirit and deep scientific expertise in collagen engineering applied specifically to the unmet needs of complex wound management”, as David Wemans, VP Regenerative Technologies at Geistlich, explains in the statement. “We are confident that clinicians will see meaningful outcomes with DermaForm.”
DermaForm fills a major gap in the area of wound care also in the view of Tom Dion, EVP & Chief Commercial Officer at StimLabs. “Clinicians managing large, complex wounds need a product that is not only effective but also practical – easy to apply, easy to store, and easy to incorporate into their existing workflow”, as Dion explains in an announcement issued by his company. “DermaForm delivers on all three. It is shelf-stable at room temperature, pourable directly from the vial, and has the inherent benefits of a particulate device. We expect strong uptake from hospital-based wound care teams”.
